Genomic and transcriptomic characterization of small bowel adenocarcinoma

Karan Pandya, MD, Rutgers University, New Brunswick, NJ, describes the differences between small bowel adenocarcinoma (SBA) and colorectal cancer (CRC), which both often have similar treatment regimens. In an analysis of 823 patients with small bowel adenocarcinoma, non-BRAF V600E mutations were more frequent and unlike in CRC, the majority of HER2 mutations were point mutations. Despite the resulting differential mutations present restricting treatment options, RSPO3 fusions enable the possible use of Porcupine inhibitors and the use of immunotherapies such as checkpoint inhibitors represent possible therapies for SBA. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.